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ild cognitive impairment (MCI) represents a
clinical construct that identifies an intermediate state of
cognitive function between that of healthy aging and
memory and cognitive deficits associated with frank
dementia. In most cases, the definition of MCI is
intended to be applicable to those persons in the inter-
mediate state of memory and cognitive impairment who
are destined, if they live long enough, to meet criteria, at
least clinically, for dementia or Alzheimer’s disease (AD).
Although the causes of dementia and therefore MCI can
vary widely, we will limit the discussion of the neu-
ropathology of MCI to the role of postmortem neu-
ropathological and neurobiological features that are com-
monly associated with AD. The criteria and definitions
for MCI as initially described by the Canadian Study of
Health and Aging,
1,2 Reisberg et al,
3-7 and Flicker
8 in the
late 1980s were relatively broad and permissive.
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The number of studies that have investigated the neuropathology of mild cognitive impairment (MCI) is small, but
growing. In this paper we have restricted our focus to the consideration of the presence and extent of postmortem
findings relevant to the neuropathology of Alzheimer’s disease. We have drawn from studies that have investigated
the postmortem neurobiology of the brains of persons with cognitive function at the interface between unimpaired
normal function and mild but definite dementia. The data derived from these studies suggest that i) the brains of per-
sons with MCI evidence significant neuropathological and neurobiological changes relative to those without cogni-
tive impairment; ii) in general, the neuropathological and neurobiological changes are qualitatively similar to those
observed in the brains of persons with frank AD-like dementia; and iii) the neuropathological and neurobiological
brain changes associated with MCI are quantitatively less than those of persons who meet criteria for dementia. Thus,
the available, albeit limited, data suggests that MCI is associated with the early stages of the neurobiological and neu-
ropathological changes that culminate in the florid lesions of AD; including the accumulation of neuritic plaques, neu-
rofibrillary tangles, synaptic and neurotransmitter associated deficits, and significant neuronal cell death.     
© 2009, LLS SAS Dialogues Clin Neurosci. 2009;11:171-179.Subsequent clinical studies suggested that some individ-
uals with MCI remain in this intermediate stage of cog-
nitive function for longer periods of time than expected.
The criteria/definitions were then further refined to
include amnestic MCI (ie, predominantly memory
impairment cases expected to be predisposed to progress
to dementia) and nonamnestic MCI (ie, non-memory-
associated mild cognitive impairment cases who may not
necessarily progress to frank dementia).
9,10Amnestic and
nonamnestic MCI can be further subdivided to include
single or multiple cognitive domains (see refs 11,12 for
an MCI algorithm). As in the diagnosis of AD and
dementia, the criteria for cognitive impairment in any
domain are applicable to a change in cognition, memory
or otherwise, from a prior level of functioning. Other
classification schemes have also been used to define the
cognitive space between healthy cognition and demen-
tia.
9,13 One example is the use of the clinical dementia rat-
ing (CDR)
14 scale and definition of MCI as questionable
dementia (CDR score of 0.5). Notably, as indicated
below, many studies of the neuropathological features of
MCI have used the CDR=0.5 metric to define MCI. It
must be emphasized, however, that despite the fact that
MCI is often used as a global framework to define the
space between no cognitive impairment and frank
dementia, different conceptualizations and definitions
vary considerably and influence how individuals are clas-
sified. One recent study
15 that explored the usage of four
commonly used definitions and criteria found consider-
able variation between them (from 5.9% to 32.4% of
studied individuals classified as MCI depending on the
metric used). Of the 34 people studied, no subject was
classified as MCI by all four definitions.
The neuroimaging literature of pathological changes
associated with MCI is more extensive than the post-
mortem literature. This is in part to due to the progres-
sion of persons with MCI to more severe forms of
dementia before they die and come to autopsy. The neu-
roimaging literature
16-23 implicates pathological changes,
such as atrophy and sclerosis, in the hippocampus and
entorhinal cortex, and the likely development of amyloid
plaques based on molecular neuroimaging, by positron
emission tomography (PET) using an amyloid-β-peptide
(Aβ) ligand known as Pittsburgh Compound B (PiB).
24,25
The validity of PET studies with PiB has been bolstered
by a limited number of in vivo imaging and postmortem
neuropathology studies,
26,27 and one recent study that
combined PiB-PET with neuropathological study of
brain biopsy specimens.
28,29The neuroimaging literature
in MCI has been reviewed recently.
11,30
An issue that influences how we interpret postmortem
neurobiological studies of MCI and dementia is the way
that neuropathological criteria are applied and the way
that experiments are designed. It is important to recog-
nize that neuropathological criteria such as the CERAD
31
or NIA/Reagan
32 criteria are probabilistic constructs
designed to distinguish between persons with significant
AD neuropathology and those without. The probabilis-
tic nature of these criteria stems from the recognition
that there are significant instances of persons with no
cognitive impairment who nevertheless evidence unusu-
ally high levels of AD-associated neuropathology,
33,34 and
instances of persons with clinically diagnosed AD-like
dementia who present with little or no discernable neu-
ropathology. In addition, age, the most significant risk
factor for dementia, also plays a role in the extent of AD-
associated neuropathology observed in the brain, irre-
spective of the presence or absence of dementia symp-
toms. Thus, if questions regarding the presence, absence,
or extent of neuropathologic lesions or neurobiological
changes are framed in the context of whether persons
with MCI meet neuropathological criteria for AD, the
results may lead to very different conclusions than if the
questions are framed within the context of whether per-
sons with MCI present with lesion densities or neurobi-
ological changes that are different from those without
cognitive impairments. In general, the brains of persons
with MCI do not meet neuropathological criteria for AD,
but they nevertheless evidence pathological features that
are qualitatively, but not quantitatively, AD-like (please
see below). An illustrative example is a study of the asso-
ciation of neuritic plaques with cognitive compromise as
defined by the CDR.
35 Persons with no cognitive impair-
ment were compared with those with different levels of
impairment. Persons with CDRs of 0.5 (ie, MCI), had
cortical neuritic plaque densities that were significantly
higher than that of persons with intact cognition. Yet, the
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172
Selected abbreviations and acronyms
AD Alzheimer's disease
CDR Clinical dementia rating
MCI mild cognitive impairment
MRI magnetic resonance imaging
NBM nucleus basalis of Meynert
NFT neurofibrillary tangles
NP neuritic plaquesmajority of the studied sample with CDR scores of 0.5
and even those with CDR scores of 1 did not meet
accepted neuropathological criteria for AD.
31,32,36 Similar
results have been reported using different MCI classifi-
cation schemes and different metrics of AD-associated
lesion densities (eg, ref 37).
General neuropathology
The majority of the studies of the neuropathology of MCI,
especially degenerative/amnestic MCI,
11,12 suggest that in
most instances MCI is associated with a less fervent man-
ifestation of the neuropathologies that are generally asso-
ciated with dementia. Unselected MCI samples derived
from memory clinic or general geriatric populations evi-
dence a variety of neuropathologic lesions such as those
associated with diffuse Lewy body disease, cerebrovascu-
lar disease, ischemic changes and hippocampal sclerosis,
argtrophilic grain disease, Parkinson’s disease, and, of
course, AD (eg, refs 37-40). Nearly invariably, the extent
of these lesions is considerably less than those observed in
persons with frank dementia. In general, relative to per-
sons with intact cognition, the frequency of AD-associated
neuropathology in persons with MCI, especially those with
amnestic MCI, is significantly greater than other neu-
ropathologic lesions associated with dementia.
40,41
Hallmark lesions of AD
Alzheimer’s disease is characterized by extracellular neu-
ritic plaques (NP) and intracellular neurofibrillary tan-
gles (NFT).
35,41-47As mentioned previously, the extent, dis-
tribution, and density of these lesions are used by most
diagnostic and staging strategies for AD. Most studies of
MCI have shown that the density and distribution of
these hallmark lesions and their less “mature” lesion vari-
ants (eg, NP—diffuse plaques, cored plaques; NFT—pre-
NFT hyperphosphorylated or conformationally altered
tau) is significantly increased in the brains of persons
with MCI.
35,38,39,42,44,48-50 Early studies by Morris et al
48,49
showed that persons with CDR scores of 0.5, ie, question-
able dementia/MCI, evidenced statistically significant
increases in the density of plaques, especially diffuse
plaques, in the temporal cortex. The density of plaques
increased with increasing dementia severity and the pro-
portion of plaques shifted from diffuse to more mature
variants (eg, cored and neuritic). Our studies of neuritic
plaques
35 showed a similar pattern where persons with
CDR=0.5 evidenced significantly greater number of NPs
in the neocortex than age-matched cognitively intact con-
trols, but fewer NPs than persons with frank dementia
(ie, CDR>1). Similar changes were noted recently in a
study where the definition of MCI was restricted to those
persons with amnestic MCI as defined by Petersen et
al.
10,11,51 In that study,
39 the numbers of neocortical diffuse
plaques were not significantly elevated in MCI, but the
numbers of NPs were significantly higher than those in
persons with intact cognition. Since the pathogenic con-
stituent of NPs is the Aβ peptide, it is not surprising that
Aβ levels in the brains of persons with MCI are also sig-
nificantly elevated.
52-54 Just as diffuse plaques may repre-
sent premature NPs, oligomeric forms of Aβ may pre-
cede the diffuse aggregates and represent an even earlier
neurotoxic form of Aβ.
55The question of the association
of oligomeric forms of Aβ in MCI is an area of active cur-
rent investigation by many laboratories (see below). As
mentioned previously, these observations of plaque
involvement in MCI are consistent with neuroimaging/
PET studies of MCI using PiB.
28,29
Generally similar conclusions can be drawn regarding the
involvement of NFTs in MCI.
33,47,50,56-60 However, the pre-
cise distribution of NFTs within neocortical and medial
temporal lobe structures and the phosphorylation or con-
formational state of the tau protein constituent of NFTs
may be critical factors. Several studies have found that
the density of NFTs in the hippocampus and the parahip-
pocampal gyrus as well as the amygdala increase signif-
icantly in persons with MCI (eg, refs 39,49). Most studies
find that the NFT involvement in neocortical regions is
associated with more advanced cognitive impairment,
supporting the staged development of NFT pathology as
a function of AD progression.
61,62 The development of
early NFT pathology and its progression is further sup-
ported by cellular studies. Stereological analyses have
shown that, at least in the neocortex, MCI or early AD-
associated NFTs develop first in degeneration-suscepti-
ble large neurons of layers III and V of the frontal cor-
tex, implicating long-track association circuits of the
brain.
47 Multivariate analyses of NFTs with an emphasis
on early conformational changes of tau in the frontal cor-
tex support these observations.
42 On the other hand,
other studies (eg, refs 44,63) have noted an age-depen-
dent increase in NFTs, like those cited above, but they
have found NFT association with cognitive function rel-
atively late in the course of disease. A possible explana-
tion of these apparently discrepant results may lie in the
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173way that NFTs develop. Just as NPs are thought to evolve
(from diffuse to cored to neuritic), NFTs develop gradu-
ally through changes in protein structure. NFTs are com-
prised of paired-helical filaments that are aggregates of
the microtubule-associated protein tau
64-68 that have
undergone abnormal conformation and phosphoryla-
tion.
69-72 Several studies suggest that even when an asso-
ciation between MCI and histopathological indices of
NFTs is not identified, changes in the phosphorylation or
conformation state of tau are associated with MCI (eg
refs 42,73). In addition, recent studies suggest that the
neurofilament protein tau within the AD-vulnerable
cholinergic neurons of the nucleus basalis of Meynert
(NBM)
74 and noradrenergic neurons within the brain-
stem locus ceruleus
75 become conformationally altered
or hyperphosphorylated in MCI.
60
Neuronal and synaptic loss
Although NPs and NFTs are hallmark and diagnostic
lesions for AD, their net effect on cognitive function may
be expressed through cell death and/or loss of synapses.
Only a few studies have examined neuronal or synaptic
loss in MCI directly, eg, refs 76-80. Several of these stud-
ies
76,78,81 used stereological techniques and found signifi-
cant loss of neurons in the frontal cortex, the entorhinal
cortex and the CA1 field of the hippocampus. An inter-
esting feature of one of these studies
76 was that the neu-
ronal loss exceeded the number of NFT-bearing neurons.
This observation could suggest that in addition to NFTs,
other factors influence neuronal loss in MCI and AD; but
it can also be argued that the greater neuronal loss
reflects the death and elimination of NFT-bearing neu-
rons, and the survival of other NFT-bearing neurons that
have not yet been eliminated from the neuronal pool. On
the other hand, other studies
79 have noted that detectable
cell loss does not occur in the brains of persons with
MCI, but is evident in the brain of more cognitively
impaired early AD persons. Credence for this hypothe-
sis can be derived by the observation that in at least one
of the studies reporting MCI-associated cell loss,
78 the
subjects included in the MCI group evidenced sufficient
NP and NFT lesions to meet diagnostic criteria for AD.
This observation raises the possibility that persons clas-
sified as MCI in this study were in a more advanced stage
of cognitive impairment than those assessed in some of
the other studies (eg, ref 79). Clearly, the number of stud-
ies that have investigated the question of neuronal loss
in MCI, and the number of cases of MCI samples in each
of these studies is too small to justify firm conclusions.
However, the cited studies all suggest that neuronal loss
is a feature of cognitive compromise that can be
observed early in the dementing process, even if absent
at the very earliest stages of impairment. 
That more subtle cellular changes occur also in MCI is
supported by recent studies that suggest that, while some
neurons are lost in MCI, others, especially those in the
cerebral cortex, hippocampus, and NBM, undergo hyper-
trophy of their nuclear volumes.
82,83 It has been hypoth-
esized
83 that these cellular changes may reflect a compen-
satory state that forestalls cell death in MCI. Although
the numbers of studies are still very limited, there is
growing emphasis on exposing the neurobiological mech-
anisms responsible for cell death in MCI. The toxicity of
Aβ and Aβ oligomers mentioned above is one example,
as is the susceptibility of some neurons to oxidative
stress
84,85 and the expression and response to neurotrophic
factors.
86-88 One recently emergent concept that is consis-
tent with neuronal loss in MCI and AD is the abnormal
re-execution of cell division/cycle programs in neurons
and the abnormal expression of cell-cycle related genes
and proteins.
89-91 Unquestionably, these divergent mech-
anisms may not be mutually exclusive and many other
cellular processes are likely to play important roles in
MCI-associated cell loss. These and other similar studies
underscore the clear imperative for future research to
more fully describe the mechanistic processes that con-
tribute to neuronal death.
Early studies (eg, ref 74), that have since been replicated
multiple times, showed that the cholinergic neurons of
the NBM were especially vulnerable to degeneration in
AD. This finding was highly consistent with even earlier
observations that the activities of cholinergic enzymes
are significantly reduced in AD.
92-94 Several studies (eg,
refs 95,96) indicated that although the cholinergic deficits
in AD were profound, they became manifest only in the
late stages of cognitive impairment. More recent
reports
97,98 have suggested that MCI is associated with
more subtle cholinergic abnormalities that may be
indicative of compensatory changes. These detailed stud-
ies of MCI found that the activities of cholinergic marker
enzymes rose in multiple cortical regions and in the hip-
pocampus of persons with MCI, but then returned to lev-
els comparable to that of nondemented individuals in
early AD and early dementia cases before decreasing to
below normal in advanced AD. That the MCI-associated
Basic research
174changes in the activities of cholinergic marker enzymes
are likely related to changes in NBM neurons has been
shown by elegant gene expression profiling studies of
individually dissected neurons.
87This study showed that
the composition of neurotrophin/cholinotrophic response
elements in individual cholinergic neurons of the nucleus
basalis of Meynert is significantly altered in MCI.
A parsimonious corollary to neuronal loss is that it
should lead to a decrease in the number of synapses.
However, proliferation of synapses compensatory to neu-
ronal loss could also occur, as could reductions in synap-
tic numbers, proteins and function in the absence of neu-
ronal loss. Early pioneering studies, (eg, refs 99-101),
suggested that synapse loss was a strong correlate of cog-
nitive compromise in AD, but these studies did not
address the question of synapse loss in MCI directly.
Unbiased stereological studies
77,102 have shown that there
is indeed significant synaptic loss associated with MCI in
the dentate gyrus and the CA1 field of the hippocam-
pus
77,102 and that the magnitude of synaptic loss increases
with increasing cognitive impairmant.
77 Many neurobio-
logical mechanisms can be involved in this MCI-associ-
ated loss of synapses, including toxicity of Aβ
oligomers.
103 More biochemical studies
104 have suggested
that the changes in synaptic function may occur non-uni-
formly in different parts of the brain and that different
synapse-associated proteins, including markers of den-
dritic spine plasticity (drebrin), may be differentially
affected in MCI.
Neuropathology of MCI in the oldest old
Until recently, most studies of the neurobiological sub-
strates of dementia and AD have focused on persons in
the 65 to 85 years of age range or have not specifically
differentiated between different age groups within the
elderly population. However, US Census Bureau data
and projections
105,106 show that the number of Americans
over the age of 85 (4.4 million in 2001) will rise signifi-
cantly by 2010 to 5.8 million and will quadruple to 19.3
million by 2050 (http://www.census.gov/population/www/
projections/natdet-D1A.html). Of these 19.3 million, 8
million are predicted to develop dementia,
107 with the
prevalence of dementia increasing from 13% in 77- to-84
year-olds to 48% in persons 95 years old and older.
108
Similarly, the incidence of dementia increases from 1%
at age 65 to 21% to 47% at ages 85 and older.
109-111 Only
recently have studies begun to distinguish between
“young-old,” often defined as those younger than 85 or
90, and oldest-old individuals (persons over the age of 85
or 90). That understanding the neurobiological substrates
of dementia and MCI in this age group is important is
highlighted by a recent study
112 suggesting that even after
controlling for physical disorders, 5-year mortality in per-
sons 95 years and older is significantly higher in
demented individuals than in those who are cognitively
intact (96% vs 73%, respectively). In fact, dementia was
a stronger predictor of mortality in this population than
cardiovascular disease, cancer or male sex. The impor-
tance of this distinction has become even more apparent
from recent evidence suggesting that the neuropatholog-
ical substrates of dementia may be different in these two
broad age categories. Accumulating evidence suggests
that nonagenarians and centenarians display different
patterns of cortical vulnerability to the neurodegenera-
tive process compared with younger elderly, and it is not
known whether correlations between clinical severity and
neuropathological stages remain valid in this age group.
Several investigations have noted that oldest-old partic-
ipants who die with dementia frequently do not have the
high amounts of the hallmark NP and NFT neuropatho-
logical lesions generally associated with dementia and/or
AD
113-121 (but see ref 43). One of these studies directly
compared the density of neocortical and hippocampal
NPs and NFTs in the brains of young-old individuals with
CDR scores of 0.5, to similarly impaired oldest-old per-
sons.
121As expected from the foregoing, a relatively high
number of NPs and NFTs were associated with CDR 0.5
in young-old individuals, but the density of NPs and
NFTs was not significantly higher in the brains of CDR
0.5 oldest-old persons. The failure of NFT-based neu-
ropathological staging to distinguish between persons
without cognitive impairment and those with MCI has
also been reported in nonagenarians.
122 Interestingly, the
association of synaptic abnormalities and dementia
appear to be relatively constant between young-old and
oldest-old persons with frank dementia
120 raising the pos-
sibility that the association of synaptic proteins with MCI
noted in young old persons (see above) will also be true
of oldest-old persons with MCI. Even when evidence of
MCI associated neuropathology is found in the oldest-
old, the neuroanatomical distribution of the lesions
appears to vary from that of young-old persons. One
quantitative study
46 that investigated the distribution of
NPs and NFTS within the different fields of the hip-
pocampus in mild AD cases found modest associations
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175of NFTs in the CA2 field of the hippocampus in the old-
est-old, whereas NFTs in the CA1 field, which is more
closely associated with dementia in younger persons,
appeared to be relatively spared.
Concluding remarks
Given the clinical relevance of MCI and its importance
and implications for the development of treatment
approaches for dementia in the elderly, it is disappoint-
ing that direct postmortem and neurobiological studies
of MCI are insufficient for firm conclusions. Many of the
existing studies are marred by small sample sizes, insuf-
ficient clinical characterization, and experimental and
practical constraints on consideration of crucial variables
such as age, symptom duration, and sex. Despite these
limitations, the available data suggests that similar to the
continuum of cognitive impairment, the AD-associated
neurobiology and neuropathology of MCI are typified by
prediagnostic mild changes that are qualitatively simi-
lar to those associated with the pathophysiology of AD
dementia. Neuropathological, anatomical, and neurobi-
ological studies of MCI in the oldest-old are even more
sparse than age-indiscriminate studies or studies in
young-old persons.   ❏
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¿Existe una diferencia neuropatológica entre
el deterioro cognitivo leve y la demencia?
El número de estudios que han investigado la neu-
ropatología del deterioro cognitivo leve (DCL) es
pequeño, pero creciente. En este artículo el foco de
atención se ha centrado en la presencia y extensión
de los hallazgos postmortem relevantes en la neu-
ropatología de la Enfermedad de Alzheimer (EA).
Se ha recurrido a estudios que han investigado la
neurobiología postmortem de cerebros de perso-
nas con función cognitiva en la interfaz entre la
función normal sin deterioro y la demencia confir-
mada, pero leve. Los datos derivados de estos estu-
dios sugieren que: 1) los cerebros de personas con
DCL evidencian cambios neuropatológicos y neuro-
biológicos significativos en relación con los sujetos
sin deterioro cognitivo, 2) en general, los cambios
neuropatológicos y neurobiológicos son cualitati-
vamente similares a los observados en los cerebros
de personas con franca demencia tipo EA y 3) los
cambios cerebrales neuropatológicos y neurobioló-
gicos asociados con el DCL son cuantitativamente
menores que los de personas que cumplen los cri-
terios para demencia. Por lo tanto, la información
disponible - aunque limitada- sugiere que el DCL
está asociado con las etapas precoces de los cam-
bios neurobiológicos y neuropatológicos que culmi-
nan en las lesiones floridas de la EA, incluyendo la
acumulación de placas neuríticas, ovillos neurofibri-
lares, déficit sináptico y de neurotransmisores aso-
ciados, y significativa muerte celular neuronal. 
Y a-t-il une différence neuropathologique
entre le déficit cognitif léger et la démence ?
Le nombre d’études ayant analysé la neuropatholo-
gie du déficit cognitif léger (DCL) est faible mais
croissant. Cet article s’intéresse exclusivement à
l’existence et à l’importance des observations post-
mortem applicables à la neuropathologie de la mala-
die d’Alzheimer (MA). Nos conclusions sont issues
d’études ayant analysé la neurobiologie postmortem
de cerveaux de personnes souffrant d’une fonction
cognitive intermédiaire entre une fonction normale
non altérée et une démence légère mais constituée.
Les données issues de ces études montrent : 1) les
cerveaux des personnes ayant un DCL manifestent
des changements neuropathologiques et neurobio-
logiques significatifs en comparaison de ceux
indemnes de déficit cognitif ; 2) en général, les chan-
gements neuropathologiques et neurobiologiques
sont qualitativement identiques à ceux observés dans
les cerveaux de personnes ayant une démence
franche semblable à la MA ; et 3) les modifications
cérébrales neuropathologiques et neurobiologiques
associées à la DCL sont quantitativement moins
importantes que celles des personnes atteintes de
démence. Ainsi, les données disponibles, bien que
limitées, suggèrent que le DCL est associé aux stades
précoces des changements neuropathologiques et
neurobiologiques qui mènent aux lourdes lésions de
la MA, comprenant une accumulation de plaques
séniles, des dégénérescences neurofibrillaires, des
déficits associés aux synapses et aux neurotransmet-
teurs et une mort cellulaire neuronale significative.177
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